Skip to content
  • Home
  • JMO Companion App
YouTube Facebook LinkedIn
YouTube Facebook LinkedIn
  • JMO Companion App
Teaching for ImpactTeaching for Impact
  • Programs
    • VCE Program (RESET)
    • Medicine Program
      • Pre-Clinical Lecture Series
      • OSCE Video Series
      • A3 Tutorials
      • Virtual Ward Round Series
      • Clinical Skills Booklet
    • HSC Program
  • Discover
    • Volunteer
Volunteer
Teaching for ImpactTeaching for Impact
Popular Search heart failurehypertensionpneumothoraxhypernatrehypernat

Skills

  • Approach to MET call
  • Indwelling catheter
  • Basic Life Support (BLS) – Adults

Cardiology

  • Acute coronary syndrome
  • Ventricular tachycardia
  • Supraventricular tachycardia
  • Bradycardia
  • Chest pain
  • Heart failure
  • Hypertension

Endocrinology

  • Hypophosphataemia
  • Hypoglycaemia
  • Diabetic ketoacidosis and hyperosmolar hyperglycaemic state
  • Vitamin D deficiency
  • Hypernatremia
  • Hypokalaemia
  • Hyperkalaemia
  • Hypercalcaemia
  • Hyperglycaemia
  • Hypocalcaemia

Urology

  • Haematuria

Palliative care

  • End-of-Life Care

Neurology

  • Acute drop in GCS
  • Vertigo
  • Headache

Respiratory

  • Pneumonia
  • COPD exacerbation
  • Hypoxia
  • Asthma exacerbation
  • Pneumothorax

Geriatrics

  • Falls

Infectious diseases

  • Urinary tract infection
  • Febrile neutropenia
  • Positive blood cultures
  • Cellulitis

Emergency

  • Epistaxis

Gastroenterology

  • Abdominal pain
  • Refeeding syndrome
  • Nausea and vomiting

Haematology

  • Oral Anticoagulants Dosing 

Nephrology

  • Oliguria

General medicine

  • Hypotension
  • Alcohol withdrawal
  • Fluids
  • Delirium
  • Home
  • jmocompanion
  • Respiratory
  • Pneumonia

Pneumonia

Table of Contents
  • Overview
  • Triage
  • Causes
  • Clinical features
  • Diagnosis
  • Investigations
  • Classification
  • Management
  • Management - Community Acquired Pneumonia
  • Management - Hospital Acquired Pneumonia
  • Management - Aspiration Pneumonia 
  • Complications of pneumonia
  • References

Overview #

Definitions

Pneumonia is an infection of the lung parenchyma (1). It can be classified by source of acquisitionas:

  • Community Acquired Pneumonia (CAP) = pneumonia that develops in the community or in a patient hospitalised for <48 hours (2)
  • Hospital Acquired Pneumonia (HAP) = pneumonia that develops in a patient hospitalised for >48 hours (3)
  • Aspiration Pneumonia = pneumonia that develops from the aspiration of pathogens (4)
  • Ventilator Associated Pneumonia (VAP) = pneumonia that develops in a patient mechanically ventilated for >48 hours (5)

Pneumonia can also be classified by causative pathogen or pattern of lung involvement (see below for more details)

Prioritisation

  • If there are signs of respiratory insufficiency or organ dysfunction, management must be made an urgent priority

Key points

  • Antibiotic therapy is based on classification of pneumonia
  • It is important to monitor response to therapy. If there is no clinical improvement with current therapy, re-evaluation is required
  • Antibiotic therapy must not be delayed for severe pneumonia

Triage #

  • Emergency requiring immediate attention: signs of respiratory insufficiency or organ dysfunction
  • Attend within 30 min – 1 hour: mild/moderate pneumonia

Causes #

Pneumonia is most commonly caused by bacterial infections including typical and atypical pathogens. Causative bacterial and viral pathogens are summarised in the following table (1): 

[TABLE TO BE DISPLAYED IN CALLOUT BOX]

Bacterial pathogensViral Pathogens
Typical:Streptococcus pneumoniae (most common cause of CAP)Haemophilus influenzae Klebsiella pneumoniaePseudomonas aeruginosaStaphylococcus aureusAtypical:Mycoplasma pneumoniaeLegionella speciesChlamydophila pneumoniae Influenza virusSARS-CoV-2RhinovirusRespiratory syncytial virusParainfluenza virusHuman MetapneumovirusAdenovirus

Clinical features #

Patients with red flags should be escalated to senior clinicians and treated as a priority. Red flags include signs of respiratory insufficiency and/or organ dysfunction (1, 6, 7):

  • Abnormal vital signs (tachypnoea, tachycardia, hypotension, oxygen desaturation)
  • Altered conscious state/confusion
  • Lactate >2 mmol/L
  • Multilobar involvement on CXR
  • Poor peripheral perfusion
  • Oliguria 

Other signs/symptoms include:

  • Cough (productive or non-productive)
  • Fever
  • Dyspnoea
  • Chills, fatigue, malaise
  • Pleuritic chest pain
  • Signs of consolidation on auscultation (crackles, dull percussion, tactile fremitus) 
  • Non-respiratory symptoms including confusion and diarrhoea (particularly in atypical pneumonia) (1, 6, 7)

Diagnosis #

Diagnosis of pneumonia can be made based on history and examination in conjunction with a CXR (1)

Investigations #

Initial investigations (1, 6, 7)

InvestigationSignificance
Sputum culture and gram stain Guides antibiotic therapy. Note that patient may not have a productive cough
Nasopharyngeal swabExclude COVID-19 and other viral infections
VBGLactate >2 mmol/L is a sign of organ dysfunction (red flag)
FBELeukocytosis and neutrophilia support infective process
UECRaised creatinine and urea associated with poorer prognosis
CRPSupports bacterial infection
Blood culturesPreferably collect prior to antibiotic therapy, but should not delay treatment. if bacteraemia present, guides antibiotic therapy
CXRConsolidation

Further investigations

Consider these if there is suspicion of an atypical pathogen.

  • Nucleic acid amplification testing (to confirm/exclude viral infection)
  • Pneumococcal urinary antigen assay
  • Legionella urinary antigen assay
  • Serological testing (e.g. serology for M. pneumonia, Legionella species, C.pneumoniae, etc.) (1, 6, 7)

Classification #

The severity of pneumonia can be classified as mild, moderate or severe using the following tools.

CURB-65 (8)  [TO BE DISPLAYED IN CALLOUT BOX]

Identifies the severity of CAP and guides the necessity of admission to hospital.

CConfusion (acute onset)1 point
UUraemia1 point
RRespiratory Rate ≥30 breaths/min1 point
BSystolic Blood Pressure ≤90 mmHg or
Diastolic Blood Pressure ≤60 mmHg
1 point
65≥65 years of age1 point

Score 0-1: <3% 30-day mortality; manage at home if safe to do so

Score 2: 9% 30-day mortality; manage as an inpatient

Score 3-5: 5-40% 30-day mortality; manage as an inpatient and consider ICU 

SMART COP (9) [TO BE DISPLAYED IN CALLOUT BOX]

Identifies likelihood of a patient requiring Intensive Respiratory or Vasopressor Support (IVRS)

SSystolic Blood Pressure ≤90 mmHg2 points
MMultilobar CXR involvement1 point
AAlbumin <35 g/L1 point
RRespiratory Rate ≥25 breaths/min (≤50 years) or
≥ 30 breaths/min (<50 years)
1 point
TTachycardia ≥125 beats/min1 point
CConfusion (acute onset)1 point
OOxygen desaturation ≤50 years: PaO₂ <70 mmHg or O₂ saturation ≤93%>50 years: PaO₂ <60 mmHg or O₂ saturation ≤90%2 points
PArterial pH <7.352 points

Score 0-2: ≤2% 30-day mortality; low risk of needing IVRS

Score 3-4: 5-13% 30-day mortality; moderate risk of needing IVRS (1 in 8)

Score 5-6: 11-18% 30-day mortality; high risk of needing IVRS (1 in 3)

Score ≥7: 33% 30-day mortality; very high risk of needing IVRS (2 in 3) 

Management #

Immediate management:

  • DRSABCD
  • MET Call/Code blue as appropriate

Non-antibiotic management (8):

  • Oxygen therapy as appropriate to maintain SpO₂ >94%
  • Oral or intravenous fluids to maintain euvolaemia
  • Analgesia if required
  • Antipyrexials if febrile

Antibiotic management:

  • The below recommendations are empirical antibiotic regimes
  • If a causative pathogen is identified, use directed antibiotic therapy

Management – Community Acquired Pneumonia #

Mild CAP

Can usually be managed in the community

Amoxicillin 1 g oral, 8-hourly

If atypical pathogens suspected, add:

Doxycycline 100 mg oral, 12-hourly OR Clarithromycin 500 mg oral, 12-hourly

If allergic to penicillins, use doxycycline

Duration of therapy: 5 – 7 days based on clinical improvement (2, 6)

Moderate CAP

Benzylpenicillin 1.2 g IV, 6-hourlyPLUS
Doxycycline 100 mg oral, 12-hourly OR Clarithromycin 500 mg oral, 12-hourly

If non-severe allergy to penicillins:

Ceftriaxone 1 g IV, 24-hourlyPLUS
Doxycycline 100 mg oral, 12-hourly OR Clarithromycin 500 mg oral, 12-hourly

If severe allergy to penicillins:

Moxifloxacin 400 mg oral, 24-hourlyPLUS
Doxycycline 100 mg oral 12-hourly OR Clarithromycin 500 mg oral, 12-hourly

Once the patient is clinically stable, can switch from IV to oral therapy. Use:

Amoxicillin 1 g oral, 8-hourlyPLUSDoxycycline 100 mg oral, 12-hourly OR Clarithromycin 500 mg oral 12-hourly

Duration of therapy: 5 – 7 days (IV + oral) based on clinical improvement (2, 6)

Severe CAP

Do not delay antibiotics for severe pneumonia. Ensure to escalate to seniors and call MET/Code Blue if required. Depending on severity, may also require discussion with ICU and/or Infectious Diseases team.

Ceftriaxone 2 g IV, 24-hourlyPLUS
Azithromycin 500 mg IV, 24-hourly

Patients may require additional therapy based on causative organism and clinical response. These cases should be escalated to seniors.

For example:

  • Staphylococcus aureus: add vancomycin IV (dose based on clinical guidelines)
  • Pseudomonas: piperacillin+tazobactam 4+0.5g IV, 6 hourly + gentamicin IV (dose based on clinical guidelines)

Once the patient is clinically stable, can switch from IV to oral therapy. Use:

Amoxicillin 1 g oral, 8-hourlyPLUSDoxycycline 100 mg oral, 12-hourly OR Clarithromycin 500 mg oral, 12-hourly

Duration of therapy: 5 – 7 days (IV + oral) based on clinical improvement (2, 6)

Management – Hospital Acquired Pneumonia #

Mild/Moderate HAP

If oral therapy is tolerated:

Amoxicillin + clavulanate 875 + 125 mg oral, 12-hourly

If non-severe allergy to penicillins:

Cefuroxime 500 mg oral, 12-hourly 

If severe allergy to penicillins:

Moxifloxacin 400 mg oral, 24-hourly

Duration of therapy: 7 days (IV + oral) based on clinical improvement

If oral therapy is not tolerated:

Ceftriaxone 1 g IV, 24-hourlyORAmoxicillin + clavulanate 1 + 0.2 g IV, 8-hourly

If severe allergy to penicillin: 

Moxifloxacin 400 mg IV, 24-hourly

Once the patient is clinically stable, can switch from IV to oral therapy as outlined above

Duration of therapy: 7 days (IV + oral) based on clinical improvement (3, 7)

Severe HAP

Piperacillin + tazobactam 4 + 0.5 g IV, 6-hourly

If severe allergy to penicillin: 

Ciprofloxacin 400 mg IV, 8-hourlyANDVancomycin IV (dose based on clinical guidelines) OR Meropenem 1 g IV, 8-hourly

Once the patient is clinically stable, can switch from IV to oral therapy as outlined above

Duration of therapy: 7 days (IV + oral) based on clinical improvement

Patients may require additional therapy based on causative organism and clinical response. These cases should be escalated to seniors.

For example:

  • Staphylococcus aureus: add vancomycin IV (dose based on clinical guidelines)
  • Pseudomonas: piperacillin+tazobactam 4+0.5g IV, 6 hourly + gentamicin IV (dose based on clinical guidelines) (3, 7)

Management – Aspiration Pneumonia  #

It is important to exclude aspiration pneumonitis which does not require antibiotic therapy.

Initial management

Treat as per CAP or HAP based on duration of hospitalisation (i.e. treat as CAP if hospitalised for <48 hours or as HAP if hospitalised for >48 hours)

If there is no clinical improvement after 48 hours of initial therapy, consider the following.

If oral therapy is tolerated:

Single drug regime:Amoxicillin + clavulanate 875 + 125 mg oral, 12-hourly OR Clindamycin 450 mg oral, 8-hourly OR Moxifloxacin 400 mg oral, 24-hourly
Dual drug regime:Amoxicillin 1 g oral, 8-hourly PLUS Metronidazole 400 mg oral, 12-hourly

If allergic to penicillin, use clindamycin or moxifloxacin.

If oral therapy is not tolerated:

Benzylpenicillin 1.2 g IV, 6-hourly PLUS Metronidazole 500 mg IV, 12-hourlyOR
Amoxicillin + clavulanate 1 + 0.2 g IV, 8-hourly

If non-severe allergy to penicillin:

Ceftriaxone 1 g IV, 24-hourly PLUS Metronidazole 500 mg IV, 12-hourly

If severe allergy to penicillin

Clindamycin 600mg IV 8-hourly OR Moxifloxacin 400 mg IV, 24-hourly

Once the patient is clinically stable, can switch from IV to oral therapy as outlined above
Duration of therapy: 5 – 7 days (IV + oral) based on clinical improvement (4, 10)

Complications of pneumonia #

Complications of pneumonia include:

  • Parapneumonic effusion
  • Empyema
  • Lung abscess

If any complications arise, treat as appropriate with the assistance of senior clinicians. (8(

References #

  1. eTG complete [Internet]. Melbourne (Vic): Therapeutic Guidelines Ltd; 2019. Pneumonia diagnosis and follow-up; [updated 2019 April; cited 2021 Sep 21]. Available from: https://tgldcdp.tg.org.au.acs.hcn.com.au/viewTopic?topicfile=pneumonia-diagnosis-follow-up&guidelineName=Antibiotic&topicNavigation=navigateTopic#toc_d1e47 
  2. eTG complete [Internet]. Melbourne (Vic): Therapeutic Guidelines Ltd; 2019. Community-acquired pneumonia in adults; [updated 2019 April; cited 2021 Sep 21]. Available from: https://tgldcdp.tg.org.au.acs.hcn.com.au/viewTopic?topicfile=community-acquired-pneumonia-adults&guidelineName=Antibiotic&topicNavigation=navigateTopic#MPS_d1e2786 
  3. eTG complete [Internet]. Melbourne (Vic): Therapeutic Guidelines Ltd; 2019. Hospital-acquired pneumonia in adults; [updated 2019 April; cited 2021 Sep 21]. Available from: https://tgldcdp.tg.org.au.acs.hcn.com.au/viewTopic?topicfile=hospital-acquired-pneumonia&guidelineName=Antibiotic&topicNavigation=navigateTopic#MPS_d1e1063 
  4. eTG complete [Internet]. Melbourne (Vic): Therapeutic Guidelines Ltd; 2019. Aspiration pneumonia; [updated 2019 April; cited 2021 Sep 21]. Available from: https://tgldcdp.tg.org.au.acs.hcn.com.au/viewTopic?topicfile=aspiration-pneumonia&guidelineName=Antibiotic&topicNavigation=navigateTopic
  5. eTG complete [Internet]. Melbourne (Vic): Therapeutic Guidelines Ltd; 2019. Ventilator-associated pneumonia; [updated 2019 April; cited 2021 Sep 21]. Available from: https://tgldcdp.tg.org.au.acs.hcn.com.au/viewTopic?topicfile=ventilator-associated-pneumonia&guidelineName=Antibiotic&topicNavigation=navigateTopic#toc_d1e865 
  6. Ramirez JA. Overview of community-acquired pneumonia in adults. In File TM, Bond S, editors.; UpToDate. [Internet]. UpToDate Inc; 2021. [updated 2021 Sep 07, cited 2021 Sep 21]. Available from: https://www.uptodate.com/contents/overview-of-community-acquired-pneumonia-in-adults?search=community%20acquired%20pneumonia&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 
  7. Klompas M. Treatment of hospital-acquired and ventilator-associated pneumonia in adults. In File TM, Bond S, editors.; UpToDate. [Internet]. UpToDate Inc; 2021. [updated 2021 Sep 02, cited 2021 Sep 21]. Available from: https://www.uptodate.com/contents/treatment-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults?search=hospital%20acquired%20pneumonia&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1
  8. Lim WS, Baudouin SV, George RC, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009 Sep 24;64(Suppl III):iii1–iii55.
  9. Charles PGP, Wolfe R, Whitby M, et al. Clin Infect Dis. 2008 Aug 1;47(3):375-384.
  10. Klompas M. Aspiration pneumonia in adults. In Sexton DJ, Hollingsworth H, editors.; UpToDate. [Internet]. UpToDate Inc; 2021. [updated 2021 Jul 26, cited 2021 Sep 21]. Available from: https://www.uptodate.com/contents/aspiration-pneumonia-in-adults?search=aspiration%20pneumonia&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1
  • Contributors

  • Reviewing Consultant/Senior Registrar

Dr Caitlin Falloon

Dr Alice Liu

What are your Feelings
Share This Article :
  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
Updated on March 27, 2023
Table of Contents
  • Overview
  • Triage
  • Causes
  • Clinical features
  • Diagnosis
  • Investigations
  • Classification
  • Management
  • Management - Community Acquired Pneumonia
  • Management - Hospital Acquired Pneumonia
  • Management - Aspiration Pneumonia 
  • Complications of pneumonia
  • References

Teaching for Impact

Our mission as a group of young leaders is to create positive and meaningful change in the community through education. We offer a variety of initiatives that empower different sectors of society to realize their full potential and use their skills, knowledge, and experience to enhance the lives of those in their surroundings.

Find us on socials

YouTube Facebook Twitter Instagram
  • Privacy Policy
  • Cookie Policy
  • Terms and conditions

Made with ♥ for the community